P
PBM
vs
S&P 500
S&P 500
Over the past 12 months, PBM has underperformed S&P 500, delivering a return of -98% compared to the S&P 500's +27% growth.
Stocks Performance
PBM vs S&P 500
Performance Gap
PBM vs S&P 500
Performance By Year
PBM vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Psyence Biomedical Ltd
Glance View
Psyence Biomedical Ltd is a CA-based company operating in industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-12-10. Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The firm has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.
